349106-80-5
349106-80-5 structure
- Name: LDCA
- Chemical Name: LDCA
- CAS Number: 349106-80-5
- Molecular Formula: C8H5Cl3FNO
- Molecular Weight: 256.49
- Catalog: Signaling Pathways Apoptosis Apoptosis
- Create Date: 2022-08-30 21:03:46
- Modify Date: 2024-09-16 21:29:26
-
LDCA is a dual-hit metabolic modulator and inhibits LDH-A enzyme activity to stimulate apoptosis in the malignant population. LDCA can be used for the research of oncogenic progression[1].
| Name | LDCA |
|---|
| Description | LDCA is a dual-hit metabolic modulator and inhibits LDH-A enzyme activity to stimulate apoptosis in the malignant population. LDCA can be used for the research of oncogenic progression[1]. |
|---|---|
| Related Catalog | |
| In Vitro | LDCA is used in combination with doxorubicin synergistically enhances the growth inhibition and induces mitochondria-mediated apoptosis by recruiting the caspase cascade, restricting migration, and obviating the clonogenic outgrowth potential of melanoma cells[1]. Cell Viability Assay[1] Cell Line: B16-F10 cells Concentration: 2-100 μM Incubation Time: 72 h Result: Arrested cell growth with a dose-dependent cytotoxic effect and had a strong synergism with LDCA. Apoptosis Analysis[1] Cell Line: B16-F10 cells Concentration: 20 μM Incubation Time: 24 h Result: Resulted in 15% death when cells exposed to LDCA and caused 40% melanoma cell death combination synergistically with doxorubicin. Immunofluorescence[1] Cell Line: B16-F10 cells Concentration: 20 μM Incubation Time: 16 h Result: Demonstrated that combination with doxorubicin resultantly affected cellular morphology with condensed and fragmented nuclei. Cell Migration Assay [1] Cell Line: B16-F10 cells Concentration: 20 μM Incubation Time: 16 h Result: Signicantly limited the migratory potential in the B16-F10 cells. |
| In Vivo | LDCA (2 mg/kg, iv., the 6th day, once) is used in combination with doxorubicin thwarts tumor growth kinetics to restrain oncogenic progression, thus accentuating survival in the model of murine melanoma[1]. Animal Model: melanoma tumor model[1] Dosage: 2 mg/kg Administration: 2 mg/kg, iv., the 6th day, once Result: Significantly increased mice survivability combination with doxorubicin, and relieved mice tumor necrosis phenomena. |
| References |
| Molecular Formula | C8H5Cl3FNO |
|---|---|
| Molecular Weight | 256.49 |